105 results about "Lowered intraocular pressure" patented technology

A method for enhancing aqueous outflow and thereby lowering intraocular pressure is disclosed. The method comprises vasodilating aqueous veins by dilating or relaxing the smooth muscle of an aqueous cavity. In one embodiment, the step of dilating or relaxing the smooth muscle of the aqueous cavity is accomplished by slowly releasing loaded smooth muscle relaxing drug at an effective dose over time. In another embodiment, the step of dilating the smooth muscle of the aqueous cavity is accomplished by introducing a smooth muscle drug through an implant.

A new and improved method and apparatus for treating glaucoma is described herein. A device for directing aqueous humor from an anterior chamber to Schlemm's canal comprises a seton, and may further comprise a pump operatively connected to the seton. The seton conducts aqueous directly from the anterior chamber to Schlemm's canal so that it can drain directly into the aqueous veins leading to the venous circulation. The seton for lowering intraocular pressure of an associated eye comprises a first tube adapted to be inserted into an associated anterior chamber of the eye; and, two wing tubes extending from the first tube. The two wing tubes are adapted to be inserted into Schlemm's canal. The two wing tubes and the first tube form a substantially continuous passageway, such that aqueous humor flows from the anterior chamber into Schlemm's canal through the substantially continuous passageway.

The present invention provides a method of treating glaucoma, the method comprising the step of placing a polymer in an eye of a patient, which biologically degrades over a period of time to release biodegradants, which are effective to lower the intraocular pressure of the patient, thereby treating glaucoma. Said polymer is preferably selected from the group consisting of polymers of lactic acid, glycolic acid and / or mixtures thereof. More preferably the polymer is a copolymer of lactic acid and glycolic acid, e.g. a copolymer comprising from 50 to 100% lactic acid and from 0 to 50% glycolic acid, by weight.

Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and / or to lower intraocular pressure.

An apparatus and method for treating presbyopia and lowering intraocular pressure employing an intra-scleral implant into an elongated cavity oriented in the radial direction of the eye. The implant has a planar portion with a longitudinal axis running therethrough and a pair of extension portions extending a distance away from said planar portion and said longitudinal axis. The implant is implanted in an incision in four quadrants of the sclera. The incisions are shaped similar to the implants. The projecting extensions into side projections of the incisions, provide an anchor to maintain the implant in the sclera.

An apparatus and method for treating glaucoma and lowering IOP is herein disclosed. A method for draining aqueous includes creating an incision in the sclera, opening a scleral flap, and inserting a drainage tube between an associated anterior chamber and at least one aqueous vein. The device has a tube with proximal and distal ends that connects between the anterior chamber and the aqueous veins, collector channels, veins, or distal veins.

The present invention provides a device for use in an eye with elevated intraocular pressure or glaucoma, the device comprising a subconjunctival conformer shaped to conform to the eye wall and a fluid director that directs or facilitates the flow of intraocular fluid out of the eye and into the subconjunctival or retrobulbar space. The present invention also provides a method of lowering intraocular pressure using the device of the present invention.

Methods, devices and systems for draining fluid from the eye and / or for reducing intraocular pressure. A passageway (e.g., an opening, puncture or incision) is formed in the lamina cribosa or elsewhere to facilitate flow of fluid from the posterior chamber of the eye to either a) a subdural location within the optic nerve or b) a location within the subarachnoid space adjacent to the optic nerve. Fluid from the posterior chamber then drains into the optic nerve or directly into the subarachnoid space, where it becomes mixed with cerebrospinal fluid. In some cases, a tubular member (e.g., a shunt or stent) may be implanted in the passageway. A particular shunt device and shunt-introducer system is provided for such purpose. A vitrectomy or vitreous liquefaction procedure may be performed to remove some or all of the vitreous body, thereby facilitating creation of the passageway and / or placement of the tubular member as well as establishing a route for subsequent drainage of aqueous humor from the anterior chamber, though the posterior chamber and outwardly though the passageway where it becomes mixed with cerebrospinal fluid.

The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with other preventive or therapeutic drug for glaucoma or ocular hypertension, their intraocular pressure lowering effects are complemented and / or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug.

In one aspect, the present invention provides an implant device for use in an eye with elevated intraocular pressure or glaucoma. In another aspect, the present invention provides a method for lowering intraocular pressure and / or treating a condition associated with elevated intraocular pressure using the implant device of the present invention.

The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein the dashed line indicates the presence or absence of a bond, the hatched wedge indicates the α (down) configuration, and the solid triangle indicates the β (up) configuration;B is a single, double, or triple covalent bond;n is 0-6;X is CH2, S or O;Y is any pharmaceutically acceptable salt of CO2H, or CO2R, CONR2, NHCH2CH2OH, N(CH2CH2OH)2, CH2OR, P(O)(OR)2, CONRSO2R, SONR2, or R is H, C1-6 alkyl or C2-6 alkenyl;R2 and R3 are C1-6 linear alkyl which may be the same or different, and may be bonded to each other such that they form a ring incorporating the carbon to which they are commonly attached;R4 is hydrogen, R, C(═O)R, or any group that is easily removed under physiological conditions such that R4 is effectively hydrogen;R5 is hydrogen or R;R6 isiv) hydrogen;v) a linear or branched hydrocarbon containing between 1 and 8 carbon atoms, which may contain one or more double or triple bonds, or oxygen or halogen derivatives of said hydrocarbon, wherein 1-3 carbon or hydrogen atoms may be substituted by O or a halogen; orvi) aryloxy, heteroaryloxy, C3-8 cycloalkyloxy, C3-8 cycloalkyl, C6-10 aryl or C3-10 heteroaryl, wherein one or more carbons is substituted with N, O, or S; and which may contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C6-10 aryl, C3-10 heteroaryl, aryloxy, heteroaryloxy, C1-6 alkyl, OR, SR, and SO2R.Some of the compounds of the present invention and some of their methods of preparation are also novel an nonobvious.

An apparatus and method for treating presbyopia and lowering intraocular pressure employing an intra-scleral implant into an elongated cavity oriented in the radial direction of the eye. The implant has a planar portion with a longitudinal axis running therethrough and a pair of extension portions extending a distance away from said planar portion and said longitudinal axis. The implant is implanted in an incision in four quadrants of the sclera. The incisions are shaped similar to the implants. The projecting extensions into side projections of the incisions, provide an anchor to maintain the implant in the sclera.

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and / or signaling of lysyl oxidase (LOX) or a lysyl oxidase-like protease (LOXL).

An eye mounted device configured to actively evacuate fluid from the anterior chamber of the eye to an exterior region or the sclera of the eye. The device employs a miniature pump powered by a photovoltaic cell which is mounted in the clear corneal tissue and which may be curved in the same shape as the eye. One or a combination of pressure sensors and timers determine the duration the device evacuates fluid from the user's eye.

This invention relates to compositions and methods for lowering intraocular pressure and treatment and / or prevention of glaucoma and ocular hypertension. The invention provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin peptide and other products of protein / gene engineered modifications of insulin for the lowering of intraocular pressure. The invention also provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein / gene engineered modifications of insulin for increasing the success of glaucoma surgical procedures. The invention further provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein / gene engineered modifications of insulin for neuroprotection of retinal ganglion cells.

A system and method for diagnosing and treating glaucoma is presented. The system imparts pressure on the anterior chamber of a eye using a coupling mechanism, while capturing three-dimensional imagery of the eye using optical coherence tomography angiography. Applying pressure in various areas of the eye, imparts changes that can help detect parts of the eye, or diagnose certain disorders related to the drainage of aqueous humor. A controller coupled to the optical coherence tomography angiography scanner may be used to guide a laser for excision of the trabecular meshwork for enhancing aqueous humor drainage thus lowering intraocular pressure and preventing glaucoma.

The present invention provides stable ophthalmic solutions comprising a compound with serotonergic 5-HT2 receptor activity and at least one stabilizer, together with methods of using such solutions to treat glaucoma and to lower intraocular pressure.

The present invention relates to cyclopentane heptenoic acid-5-cis-2-(3α-hydroxy or lower alkyloxy-5-thienylpentyl)-3, 5-dihydroxy, [1α, 2β, 3α, 5α] compounds, lower alkyl, hydroxyl lower alkyl and indole lower alkyl amides and esters thereof as potent ocular hypotensives that are particularly suited for the management of glaucoma.

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and / or signaling of connective tissue growth factor (CTGF).

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and / or signaling of connective tissue growth factor (CTGF).

The invention relates to the use of Abnormal Cannabidiols as potent ocular hypotensives, and are particularly suitable for the management of glaucoma. In particular said compounds are represented by formula I or formula or formula III

The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.

The present invention provides a device for use in an eye with elevated intraocular pressure or glaucoma, the device comprising a subconjunctival conformer shaped to conform to the eye wall and a fluid director that directs or facilitates the flow of intraocular fluid out of the eye and into the subconjunctival or retrobulbar space. The present invention also provides a method of lowering intraocular pressure using the device of the present invention.

The invention provides particular uridine di- and tri-phosphate derivatives, and pharmaceutical compositions thereof. These compounds are useful for treatment of diseases, disorders and conditions modulated by P2Y6 receptors, and particularly for lowering intraocular pressure and thereby treating ocular hypertension and / or glaucoma.

The invention provides EP2 agonists, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for lowering intraocular pressure and thereby treating glaucoma.